Stratasys and CollPlant Biotechnologies have entered a joint development and commercialization agreement to collaborate on the solution to bio-fabricate human tissues and organs using Stratasys’ P3 technology-based bioprinter and CollPlant’s rhCollagen-based bio inks. The first project focuses on the development of an industrial-scale solution for CollPlant’s regenerative breast implants program.
CollPlant is a pioneering regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-based collagen for tissue regeneration and organ manufacturing.
The new bioprinter, based on Stratasys’ precise P3 3D printing technology in combination with CollPlant’s flagship bio inks, will enable the production of CollPlant’s state-of-the-art breast implants, which are being designed to regenerate an individual’s natural breast tissue without eliciting immune response – providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.
Under the agreement, both companies have committed to mutually promoting their respective bioprinting products. Stratasys’ bioprinter will be made available to customers in conjunction with CollPlant’s bio inks, while CollPlant’s business partners and clientele will also have access to Stratasys’ bioprinter offerings.
“Through this partnership with CollPlant, we have an important opportunity to transform healthcare with bioprinting to improve the lives of patients undergoing breast augmentation or reconstruction procedures,” said Dr. Yoav Zeif, CEO of Stratasys. “This agreement is well-aligned with our strategy to deliver completesolutions for high-growth industry applications with our ecosystem of partners, and the production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerization technology are a particularly strong fit for bioprinting applications. We believe that partnering with CollPlant will enable us to accelerate the industrialization of bioprinting for regenerative medicine, and we look forward to collaborating towards the successful commercialization of CollPlant’s novel regenerative breast implants and beyond.”
“Stratasys is leading in additive manufacturing and we are excited to collaborate with them on this transformative initiative. The P3 technology allows printing with high resolution and process control, and we believe that the combined, pioneering technologies of both companies will streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants and other potential tissues and organs. We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat tissue transfer,” said Yehiel Tal, CEO of CollPlant.
In January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. Based on these positive results, CollPlant is planning to initiate a follow-up large-animal study in the second half of 2023 using commercial-size implants to support subsequent human studies and future product commercialization.